Iaso Therapeutics Receives Phase I SBIR Grant from the National Science Foundation

Iaso Therapeutics received a Phase I SBIR grant from the National Science Foundation (NSF). The grant is to study the feasibility of commercializing Iaso’s mutant Qβ (mQβ) virus-like particle. The mQβ particles are a small stable particle to which antigens of interest are chemically linked. The linked antigens are injected to elicit an immune response to the antigen. Scientists do this type of work to develop vaccines for infectious agents or disease-causing cancer cells. If successful, the work can lead to the commercial availability of a powerful carrier for vaccine development.